MX2021005913A - Agente para inhibir absorcion de hierro en las celulas. - Google Patents

Agente para inhibir absorcion de hierro en las celulas.

Info

Publication number
MX2021005913A
MX2021005913A MX2021005913A MX2021005913A MX2021005913A MX 2021005913 A MX2021005913 A MX 2021005913A MX 2021005913 A MX2021005913 A MX 2021005913A MX 2021005913 A MX2021005913 A MX 2021005913A MX 2021005913 A MX2021005913 A MX 2021005913A
Authority
MX
Mexico
Prior art keywords
inhibitor
iron uptake
cellular iron
human
present
Prior art date
Application number
MX2021005913A
Other languages
English (en)
Inventor
Lilin Zhang
Fumiko Nomura
Keiko Katsumi
Romi KOTAKA
Yuta OHIRA
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Publication of MX2021005913A publication Critical patent/MX2021005913A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Es un objeto de la presente invención proporcionar un agente para inhibir absorción de hierro en las células en donde el agente se dirige a TfR, y un agente para inhibir la unión entre Tf humana y TfR humano. La presente invención proporciona un agente para inhibir absorción de hierro en las células el cual comprende un anticuerpo el cual reconoce los aminoácidos en las posiciones 629 a 633 de un receptor de transferrina humana.
MX2021005913A 2018-11-20 2019-11-19 Agente para inhibir absorcion de hierro en las celulas. MX2021005913A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018217548 2018-11-20
JP2019167013 2019-09-13
PCT/JP2019/045227 WO2020105621A1 (ja) 2018-11-20 2019-11-19 細胞内への鉄の取り込み阻害剤

Publications (1)

Publication Number Publication Date
MX2021005913A true MX2021005913A (es) 2021-06-30

Family

ID=70774551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005913A MX2021005913A (es) 2018-11-20 2019-11-19 Agente para inhibir absorcion de hierro en las celulas.

Country Status (12)

Country Link
US (1) US20220332838A1 (es)
EP (1) EP3884959A4 (es)
JP (1) JP7410051B2 (es)
KR (1) KR20210093974A (es)
CN (1) CN113164594A (es)
AU (1) AU2019384781A1 (es)
BR (1) BR112021009768A2 (es)
CA (1) CA3120548A1 (es)
MX (1) MX2021005913A (es)
SG (1) SG11202105163UA (es)
WO (1) WO2020105621A1 (es)
ZA (1) ZA202103554B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
CN117836003A (zh) 2021-08-26 2024-04-05 株式会社英仙蛋白质科学 Ros（活性氧类）产生增强剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
PT1740616E (pt) 2004-04-30 2012-03-23 Inst Nat Sante Rech Med Anticorpo anti-rtf
CN101245107B (zh) * 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
JP2012532925A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌の処置のための化合物および方法
US9598496B2 (en) * 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
JP5939855B2 (ja) 2012-03-23 2016-06-22 国立大学法人 宮崎大学 トランスフェリン受容体抗体
JP2015524816A (ja) 2012-08-02 2015-08-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用
CN104797600A (zh) * 2012-11-08 2015-07-22 国立大学法人宫崎大学 能够特异性识别转铁蛋白受体的抗体
JP2014093958A (ja) * 2012-11-08 2014-05-22 Univ Of Miyazaki トランスフェリン受容体を特異的に認識できる抗体
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
CN114409783A (zh) * 2015-06-24 2022-04-29 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
JP2018024615A (ja) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物

Also Published As

Publication number Publication date
EP3884959A4 (en) 2022-08-10
ZA202103554B (en) 2023-01-25
EP3884959A1 (en) 2021-09-29
CA3120548A1 (en) 2020-05-28
CN113164594A (zh) 2021-07-23
JPWO2020105621A1 (ja) 2021-10-07
BR112021009768A2 (pt) 2021-10-19
WO2020105621A1 (ja) 2020-05-28
JP7410051B2 (ja) 2024-01-09
AU2019384781A1 (en) 2021-06-10
SG11202105163UA (en) 2021-06-29
KR20210093974A (ko) 2021-07-28
US20220332838A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2023001403A (es) Neoantigenos y metodos de su uso.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
EA201992683A1 (ru) Применение антител против b7h3 для лечения злокачественных опухолей в центральной нервной системе
WO2018187356A3 (en) Protein antigens and uses thereof
NZ739133A (en) Cellular targeted active ingredient delivery system
IL289897A (en) Proteins containing kallikrein-related antigen peptidase 2 binding sites and uses thereof
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2021005913A (es) Agente para inhibir absorcion de hierro en las celulas.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2018006410A (es) Proteinas de union a cd131 y usos de las mismas.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
PH12017501914A1 (en) Polypeptides targeting hiv fusion
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
CR20230469A (es) Anticuerpos anti-nectina-4 y usos de los mismos
WO2018226985A3 (en) GUIDED COMBINATORY THERAPEUTIC ANTIBODY